Polyradiculoneuropathy: Clinical Trials

97 completed, 44 recruiting, 29 unknown, 18 not yet recruiting. 39 Not applicable, 39 Phase 3, 38 Phase 2, 16 Phase 1, 6 Early Phase 1.

By phase and status

Phase	Trials	Status
Not applicable	39	Completed 18, Unknown 6, Active not recruiting 4, Terminated 4, Withdrawn 3, Recruiting 2, Enrolling by invitation 1, Not yet recruiting 1
Phase 3	39	Completed 20, Recruiting 10, Not yet recruiting 3, Terminated 2, Active not recruiting 1, Enrolling by invitation 1, Unknown 1, Withdrawn 1
Phase 2	38	Completed 16, Not yet recruiting 5, Recruiting 5, Terminated 4, Withdrawn 4, Active not recruiting 2, Unknown 2
Phase 1	16	Completed 7, Recruiting 5, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1
Early Phase 1	6	Recruiting 3, Completed 2, Not yet recruiting 1
Phase 4	5	Unknown 2, Active not recruiting 1, Completed 1, Recruiting 1

Follow Polyradiculoneuropathy: new trials by email Literature Review of Polyradiculoneuropathy trials Research Report on Polyradiculoneuropathy

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome Empasiprubart IV, Empasiprubart Placebo IV, Intravenous immunoglobulin (IVIg) - Guillain-Barré Syndrome (GBS)	Phase 2	Not yet recruiting	argenx	63	2026-12-01	2026-10-28
Clinical, Electrophysiological and Genetic Characteristics of Hereditary and Inflammatory Polyneuropathies in France Genetic and Inflammatory Polyneuropathies		Not yet recruiting	Assistance Publique - Hôpitaux de Paris	1000	2026-11-01	2026-10-01
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Immune globulin (human) 10% solution for intravenous administration - Chronic Inflammatory Demyelinating Polyneuropathy	Phase 3	Recruiting	Kedrion S.p.A.	161	2026-11-01	2026-11-05
Multimodal Characterization of Movement Trajectories in Chronic Inflammatory Demyelinating Polyneuropathy Xsens motion suit - CIDP - Chronic Inflammatory Demyelinating Polyneuropathy		Recruiting	Heinrich-Heine University, Duesseldorf	50	2026-10-23	2026-10-27
Peripheral Nerve Ultrasound in Children With Guillain-Barré Syndrome Guillain-Barre Syndrome		Not yet recruiting	Assiut University	42	2026-10-10	2026-10-08
Myocardial Changes in Pediatric Guillain-Barré Syndrome Myocardial Dysfunction, Guillain-Barre Syndrome		Not yet recruiting	Assiut University	72	2026-09-26	2026-09-25
Ultrasound-driven Stratification in CIDP Refractory CIDP, Standard-of-care treatment for CIDP - CIDP, Chronic Inflammation		Not yet recruiting	Centre Hospitalier Universitaire de Nice	30	2026-09-01	2026-07-22
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Empasiprubart IV - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)	Phase 2 / Phase 3	Not yet recruiting	argenx	6	2026-09-01	2026-06-10
Efficacy and Safety of Efgartigimod in the Treatment of Guillain-Barré Syndrome(GREAT) Intravenous immunoglobulin (IVIG), Efgartigimod Alfa-Fcab - Guillain-Barré Syndrome	Phase 2	Not yet recruiting	Beijing Tiantan Hospital	110	2026-09-01	2026-09-18
An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β	Phase 1 / Phase 2	Not yet recruiting	Zhongming Qiu	24	2026-07-15	2026-07-10
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis	Phase 1	Recruiting	Kite, A Gilead Company	57	2026-04-10	2026-10-19
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)	Phase 3	Recruiting	Grifols Therapeutics LLC	40	2026-04-02	2026-11-10
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)	Phase 1	Recruiting	Tongji Hospital	6	2026-04-01	2026-05-12
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease Whole-body Electrical Muscle Stimulation Exercise - Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis	Not applicable	Active not recruiting	University of Missouri-Columbia	50	2026-03-10	2026-11-06
Tongji NADs Cohort No active interventions - Multiple Sclerosis, NMO Spectrum Disorder		Not yet recruiting	Tongji Hospital	1550	2026-03-01	2026-01-21
Effect of PNF + Core Strengthening Exercise in Sub-acute Guillain Barre Syndrome Proprioceptive neuromuscular facilitation combined with core strengthening exercise, conventional physiotherapy - Guillain Barré Syndrome	Not applicable	Completed	Rida	32	2026-02-15	2026-08-07
Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices CIDP - Chronic Inflammatory Demyelinating Polyneuropathy		Recruiting	Heinrich-Heine University, Duesseldorf	35	2026-01-15	2026-06-10
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome immunosorbent column, intravenous immunoglobulin - Guillain-Barre Syndrome	Not applicable	Not yet recruiting	The First Affiliated Hospital of Zhengzhou University	204	2026-01-01	2025-03-12
Comparison Between Efficacy of Gabapentin and Carbamazepine in Neuropathic Pain of Guillain-Barré Syndrome Patients Gabapentin, Carbamazepine - Guillain-Barré Syndrome, Neuropathic Pain	Not applicable	Completed	Lahore General Hospital	60	2026-01-01	2026-10-30
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases CD19/BCMA-targeted CAR-T cells, Lymphodepleting Conditioning - Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG)	Early Phase 1	Recruiting	Tongji Hospital	36	2025-12-12	2026-05-12

Showing 20 of 229. Sign in to see all of them.

Narrower conditions

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (136)  ·  Guillain-Barre Syndrome (96)  ·  Myasthenia Gravis (22)  ·  Multiple Sclerosis (19)  ·  Autoimmune Diseases of the Nervous System (12)  ·  Neuromyelitis Optica (12)  ·  Autoimmune Diseases (11)  ·  Charcot-Marie-Tooth Disease (9)  ·  Myositis (9)  ·  Peripheral Nervous System Diseases (9)  ·  Rare Diseases (8)  ·  Stroke (8)  ·  Cauda Equina Syndrome (7)  ·  Disease (6)  ·  Neuromuscular Diseases (6)

Broader conditions

Nervous System Diseases (225)  ·  Polyneuropathies (224)  ·  Neuromuscular Diseases (223)  ·  Pathological Conditions, Signs and Symptoms (223)  ·  Chronic Disease (222)  ·  Disease Attributes (222)  ·  Pathologic Processes (222)  ·  Peripheral Nervous System Diseases (220)  ·  Demyelinating Diseases (219)  ·  Immune System Diseases (218)  ·  Autoimmune Diseases (211)  ·  Autoimmune Diseases of the Nervous System (210)  ·  Post-Infectious Disorders (96)  ·  Neurodegenerative Diseases (37)

Interventions

Immunoglobulins, Intravenous (22)  ·  Immunoglobulins (8)  ·  Hizentra (6)  ·  Rituximab (5)  ·  Blood Specimen Collection (4)  ·  Cyclophosphamide (4)  ·  Plasmapheresis (4)  ·  efgartigimod alfa (4)  ·  gamma-Globulins (4)  ·  Plasma Exchange (3)  ·  Vaccines (3)  ·  fludarabine (3)  ·  rozanolixizumab (3)  ·  Injections, Subcutaneous (2)  ·  Physical Therapy Modalities (2)

Sponsors

Assiut University (12)  ·  argenx (10)  ·  University of Aarhus (8)  ·  CSL Behring (5)  ·  Takeda (5)  ·  Tongji Hospital (5)  ·  Novartis Vaccines (4)  ·  Sanofi (4)  ·  Annexon, Inc. (3)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Centre Hospitalier Universitaire de Nice (3)  ·  Emory University (3)  ·  Heinrich-Heine University, Duesseldorf (3)  ·  Immunovant Sciences GmbH (3)  ·  Istituto Clinico Humanitas (3)

Countries

United States (72)  ·  France (49)  ·  Germany (36)  ·  United Kingdom (32)  ·  Italy (30)  ·  Denmark (29)  ·  Spain (26)  ·  China (25)  ·  Canada (22)  ·  Japan (20)  ·  Poland (20)  ·  Belgium (17)  ·  Netherlands (17)  ·  Argentina (16)  ·  Czechia (16)

Top investigators

Henning Andersen, Professor (2)  ·  Ahmad M. Shaddad, MD (1)  ·  Aimun Jamjoom (1)  ·  Alda S Marques, PhD (1)  ·  Alex Martino Cinnera, PhD (1)  ·  Aliae A. Hussien, MD (1)  ·  Allan Ropper, MD (1)

Results publications

PMID 42578463, PMID 18178525, PMID 38353301, PMID 38729747, PMID 12084892, PMID 12437775, PMID 12959218, PMID 14610153, PMID 15607214, PMID 15703014, PMID 16267188, PMID 16271648, PMID 16293415, PMID 16365632, PMID 16380614, PMID 16831974, PMID 16849828, PMID 16900450, PMID 19260050, PMID 19365055, PMID 19496628, PMID 19496683, PMID 19564582, PMID 19691533, PMID 20456730, PMID 20457948, PMID 20647554, PMID 20837852, PMID 21745374, PMID 22003934, PMID 23568718, PMID 23781960, PMID 24379104, PMID 24858016, PMID 26928074, PMID 27241239, PMID 27455854, PMID 27694629, PMID 27705091, PMID 27918219, PMID 28168524, PMID 28406555, PMID 28572784, PMID 28594116, PMID 28768822, PMID 28881389, PMID 28894082, PMID 28975040, PMID 29122523, PMID 29260006

NIH funding

2018 (3), 2023 (3), 2025 (3), 2016 (2), 2019 (2), 2009 (1), 2014 (1), R37AI049660 (1)